Joseph Woodard
Vermogen: 4 142 $ op 31-08-2026
Vermogen: 4 142 $ op 31-08-2026
Joseph Paul Woodard formerly worked at Bellicum Pharmaceuticals, Inc., as Senior Vice President-Clinical & Medical Affairs in 2019, Imugene Ltd., as Chief Medical Officer from 2023 to 2025, and Immune-Onc Therapeutics, Inc., as Chief Medical Officer & Senior Vice President.
Dr. Woodard received his undergraduate degree from The University of North Carolina at Charlotte and doctorate degree from UNC School of Medicine.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMUGENE LTD 0,02% | 30-06-2025 | 85.007 ( 0,02% ) | 4 142 $ | 31-08-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| IMUGENE LIMITED | Hoofd Techniek/Wetenschap/O&O | 30-05-2025 |
| BELLICUM PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-11-2019 |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Hoofd Techniek/Wetenschap/O&O | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
Imugene Ltd.
Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
The University of North Carolina at Charlotte
The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UNC School of Medicine
UNC School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau